Microbiology and Immun (Sci) : The ability to select and manipulate genetic material has led to unprecedented interest in the industrial applications of procaryotic and eucaryotic cells. Beginning in the 1970s the introduction of and subsequent refinements to recombinant DNA technology and hybridoma technology transformed the horizons of the biopharmaceutical world. This course will highlight the important events that link basic research to clinical/commercial application of new drugs and chemicals.
Terms: Winter 2020
Instructors: Robert A Murgita, Dalius J Briedis, Christos M Tsoukas, Jack P Antel, Brian Ward (Winter)
Prerequisite: At least one 200-level course in a biological or biomedical discipline or permission of instructor